206 related articles for article (PubMed ID: 23169435)
21. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
22. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Weickhardt AJ; Williams DS; Lee CK; Chionh F; Simes J; Murone C; Wilson K; Parry MM; Asadi K; Scott AM; Punt CJ; Nagtegaal ID; Price TJ; Mariadason JM; Tebbutt NC
Br J Cancer; 2015 Jun; 113(1):37-45. PubMed ID: 26125443
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.
Melichar B; Procházková-Študentová H; Vitásková D
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1253-61. PubMed ID: 23136836
[TBL] [Abstract][Full Text] [Related]
26. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenic activity of melatonin in advanced cancer patients.
Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Beatty GL; Giantonio BJ
Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
[TBL] [Abstract][Full Text] [Related]
29. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
30. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Los M; Roodhart JM; Voest EE
Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
[TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of VEGF levels in serums of colorectal cancer patients at stage IV].
Huang N; Yang L; Cao MR; Su N; Chen JZ; Lü CW; Liao WJ; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb; 29(2):278-9. PubMed ID: 19246299
[TBL] [Abstract][Full Text] [Related]
32. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
34. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
35. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
[TBL] [Abstract][Full Text] [Related]
36. Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal.
Gyanchandani R; Kim S
Clin Cancer Res; 2013 Feb; 19(4):755-7. PubMed ID: 23386694
[TBL] [Abstract][Full Text] [Related]
37. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.
Marisi G; Scarpi E; Passardi A; Nanni O; Ragazzini A; Valgiusti M; Casadei Gardini A; Neri LM; Frassineti GL; Amadori D; Ulivi P
Sci Rep; 2017 May; 7(1):1293. PubMed ID: 28465540
[TBL] [Abstract][Full Text] [Related]
38. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
Nixon AB; Pang H; Starr MD; Friedman PN; Bertagnolli MM; Kindler HL; Goldberg RM; Venook AP; Hurwitz HI;
Clin Cancer Res; 2013 Dec; 19(24):6957-66. PubMed ID: 24097873
[TBL] [Abstract][Full Text] [Related]
40. Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
Divella R; Daniele A; DE Luca R; Simone M; Naglieri E; Savino E; Abbate I; Gadaleta CD; Ranieri G
Anticancer Res; 2017 Sep; 37(9):4867-4871. PubMed ID: 28870907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
